EA201992058A1 - VACCINE - Google Patents

VACCINE

Info

Publication number
EA201992058A1
EA201992058A1 EA201992058A EA201992058A EA201992058A1 EA 201992058 A1 EA201992058 A1 EA 201992058A1 EA 201992058 A EA201992058 A EA 201992058A EA 201992058 A EA201992058 A EA 201992058A EA 201992058 A1 EA201992058 A1 EA 201992058A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
treatment
methods
relates
polypeptides
Prior art date
Application number
EA201992058A
Other languages
Russian (ru)
Inventor
Юлианна Лисиэиц
Левенте Мольнар
Эникё Тёке
Йожеф ТОТ
Оршойа Лоринц
Жольт Чисовски
Эстер Шомодьи
Каталин Пантья
Моника Медьеши
Original Assignee
Треош Био Зрт.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Треош Био Зрт. filed Critical Треош Био Зрт.
Priority claimed from PCT/EP2018/055230 external-priority patent/WO2018158455A1/en
Publication of EA201992058A1 publication Critical patent/EA201992058A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к полипептидам и фармацевтическим композициям, содержащим полипептиды, которые находят применение в профилактике или лечении рака, особенно рака молочной железы, рака яичников и колоректального рака. Изобретение также относится к способам индуцирования ответа цитотоксического Т-лимфоцита у субъекта или лечения рака путем введения фармацевтической композиции, содержащей пептиды, и способам сопутствующей диагностики для идентификации субъектов для лечения. Пептиды содержат Т-лимфоцитарные эпитопы, которые являются иммуногенными у большого процента пациентов.The present invention relates to polypeptides and pharmaceutical compositions containing polypeptides that are used in the prevention or treatment of cancer, especially breast cancer, ovarian cancer and colorectal cancer. The invention also relates to methods for inducing a cytotoxic T-lymphocyte response in a subject or treating cancer by administering a pharmaceutical composition containing peptides, and methods of concomitant diagnosis for identifying subjects for treatment. Peptides contain T-lymphocytic epitopes, which are immunogenic in a large percentage of patients.

EA201992058A 2017-03-09 2018-03-02 VACCINE EA201992058A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1703809.2A GB201703809D0 (en) 2017-03-09 2017-03-09 Vaccine
PCT/EP2018/055230 WO2018158455A1 (en) 2017-03-03 2018-03-02 Peptide vaccines

Publications (1)

Publication Number Publication Date
EA201992058A1 true EA201992058A1 (en) 2020-03-12

Family

ID=58605461

Family Applications (3)

Application Number Title Priority Date Filing Date
EA201992057A EA201992057A1 (en) 2017-03-09 2018-03-02 PERSONALIZED PLATFORM FOR IDENTIFICATION OF AN IMMUNOGENOUS PEPTIDE
EA201992059A EA201992059A1 (en) 2017-03-09 2018-03-02 PLATFORM FOR IDENTIFICATION OF IMMUNOGENOUS PEPTIDES OF THE POPULATION LEVEL
EA201992058A EA201992058A1 (en) 2017-03-09 2018-03-02 VACCINE

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EA201992057A EA201992057A1 (en) 2017-03-09 2018-03-02 PERSONALIZED PLATFORM FOR IDENTIFICATION OF AN IMMUNOGENOUS PEPTIDE
EA201992059A EA201992059A1 (en) 2017-03-09 2018-03-02 PLATFORM FOR IDENTIFICATION OF IMMUNOGENOUS PEPTIDES OF THE POPULATION LEVEL

Country Status (2)

Country Link
EA (3) EA201992057A1 (en)
GB (1) GB201703809D0 (en)

Also Published As

Publication number Publication date
EA201992057A1 (en) 2020-03-06
EA201992059A1 (en) 2020-03-31
GB201703809D0 (en) 2017-04-26

Similar Documents

Publication Publication Date Title
MX2019010459A (en) Peptide vaccines.
CY1122953T1 (en) A NOVEL COMPLEX INCLUDING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGENT FOR THE TREATMENT OF RECTHOCOL CANCER
EA201792501A1 (en) VACCINES FOR THE TREATMENT AND PREVENTION OF CANCER
EA201992590A1 (en) STABLE COMPOSITIONS OF ANTIBODIES TO THE RECIPE OF PROGRAMMABLE DAMAGE 1 (PD-1) AND WAYS OF THEIR APPLICATION
EA201790674A1 (en) CYTOTOXIC INDUCING THERAPEUTIC AGENT
MX2019002968A (en) Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer.
EA201691059A1 (en) PEPTIDOMYMETICS COMPOUNDS AND THEIR CONJUGATES CONTAINING ANTIBODY AND MEDICINE
EA202190669A1 (en) PROCESS FOR OBTAINING VACCINE COMPOSITION
EA201690159A1 (en) METHODS AND COMPOSITIONS FOR CANCER TREATMENT
EA201591579A1 (en) METHODS OF TREATMENT OF CROWN DISEASE WITH ANTI-IL-23 ANTIBODIES
CY1121734T1 (en) MUTANT OspA FRAGMENTS AND METHODS AND USES THEREOF
NZ721500A (en) Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
MX2019003970A (en) Immunogenic arginase peptides.
CO2021004019A2 (en) Peptide vaccines
MX2022002635A (en) Angiopoietin-like 4 antibodies and methods of use.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA202090319A1 (en) PEPTIDE CONJUGATES, CONJUGATION METHOD AND THEIR USE
EA202190057A1 (en) SOLUBILIZED APIRAZES, METHODS AND APPLICATION
EA202092861A1 (en) MALIGNANT TUMOR SPECIFIC T-CELL RECEPTORS
EA202191515A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING APIXABAN
CL2021001479A1 (en) peptide; use of compositions; pharmaceutical composition; use of an antibody for therapy; use of an antibody for elisa, immunohistochemistry and/or imaging; t cell receptor; and use of an activated cytotoxic t-lymphocyte (divisional of application no. 201701391)
EA201792401A1 (en) COMPOSITIONS FOR PURIFICATION OF THICK INTESTINES AND TREATMENT OF GASTROINTESTINAL DISORDERS
EA201992058A1 (en) VACCINE
EA201992852A1 (en) DOSAGE DIAGRAM FOR TESETAXEL AND CAPETSITABINE
EA202190670A1 (en) PEPTIDE VACCINES